Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Gastroenteritis » Colitis
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Intestinal Diseases » Colonic Diseases » Colitis
Description
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. MeSH
Hierarchy View
Subtype Terms (4)
Colitis, Ischemic
1 experimental drug
Colitis, Microscopic
5 drugs (4 approved, 1 experimental)
Colitis, Ulcerative
364 drugs (138 approved, 226 experimental)
Proctocolitis
2 drugs (1 approved, 1 experimental)
Approved Indicated Drugs (2)
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (5)
Phase 1 Indicated Drugs (4)
Other Experimental Indicated Drugs (5)
Organization Involved with Phase 4 Indications (79)
Centro Hospitalar Lisboa Ocidental
European Crohn´s and Colitis Organisation
Genesys Regional Medical Center
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID)
Grupo de Estudo da Doença Inflamatória Intestinal
Hospital Geral de Santo António
Hospital Provincial de Castellon
Hospital Universitario Arnau de Vilanova de Lleida
Huazhong University of Science and Technology
Istituto Clinico Humanitas - Rozzano (MI), Italy
Kliniken im Naturpark Altmuehltal
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Naturpark Kliniken Altmuehltal
People's Liberation Army of China
Postgraduate Institute of Medical Education and Research
South-Eastern Norway Regional Health Authority
Organization Involved with Phase 3 Indications (98)
Asian Institute of Gastroenterology
Asian Institutes of Gastroenterology
German Federal Ministry of Education and Research
Institut National de la Santé Et de la Recherche Médicale, France
Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf, Hamburg, Germany
National Center for Research Resources (NCRR)
Nutrition Science Partners Limited
Pharmaceutical Research Associates, Inc. (PRA)
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Technical University of Dresden
The Swedish Organization for Studies on Inflammatory Bowel Disease
Organization Involved with Phase 2 Indications (165)
Academy of Science, Czech Republic
Aleris-Hamlet Hospitals Copenhagen
Azienda Ospedaliera San Giovanni Addolorata
Azienda Ospedaliera Sant'Andrea, Roma
Bayfront Medical Center and Edward White Hospital
Casa Sollievo della Sofferenza IRCCS
Catholic University of Sacred Heart, Rome
Crohn's and Colitis Foundation
Department of Health and Human Services
Foundation for Clinical Research in IBD
Hamilton Health Sciences Corporation
Hemay Pharmaceutical PTY. LTD.
Holy Stone Healthcare Co., Ltd
Hoosier Cancer Research Network
Ivy Institute of Stem Cells Co. Ltd
JP Moulton Charitable Foundation
Katholieke Universiteit Leuven
Klinika Przewodu Pokarmowego Szpital Kliniczny Nr 1 - Lodz - Poland
Luigi Sacco University Hospital
Memorial Medical Center Foundation
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
Natrogen Therapeutics International, Inc
Queen Elizabeth Hospital NHS Foundation Trust
Reading Hospital and Medical Center
Reistone Biopharma Company Limited
Remington-Davis Clinical Research
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
Santa Barbara Cottage Hospital
Sterna Biologicals GmbH & Co. KG
Technical University of Denmark
The Eli and Edythe Broad Foundation
The University of Texas, Dallas
Third Military Medical University
University Hospital of North Norway
University of British Columbia
University of California, San Diego
University of Erlangen-Nuremberg
University of Naples Frederico II
University of Roma La Sapienza
University of Texas at Houston
Vancouver Island Health Authority
Western Norway Regional Health Authority
Organization Involved with Phase 1 Indications (28)
Organization Involved with Other Experimental Indications (30)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
